However, the expansion of supply chains and inevitable dependence on third parties has already led to serious drug supply bottlenecks in individual cases in the past. Especially for critical, life-saving drugs. The current global COVID-19 pandemic may also lead to increased restrictions or even supply bottlenecks for medicines. However, in order to secure the supply of critical drugs in Germany and Europe, this trend towards outsourcing the CMOs could be reversed. The cost advantage of relocating production is offset by the reliability of supply.
The pharmaceutical laboratories of the Tentamus Group support pharmaceutical companies that want to take production back into their own hands. Our core competencies include:
- Analytical method transfers
- In-process controls
- Cleaning validations
- Quality controls
- Stability studies
- Release analytics
- Batch certification via a separate qualified person (QP)
Off-target studies include: hydroxychloroquines, azithromycin, remdesivir, lopinavir, ritonavir, and interferon-beta
For a few days, already approved drugs have been discussed as potential drugs for the treatment of COVID-19. For example, studies of cell cultures have shown for some time now that chloroquine can prevent many viruses from multiplying, and this is also true in vitro for the novel coronavirus Sars-CoV-2. The first clinical trials with both drugs and vaccines have already started worldwide. The World Health Organization (WHO) has announced the start of a large-scale study to determine the effect of chloroquine. The demand for drugs with these active ingredients could very soon increase.
Tentamus Pharma-Laboratories take responsibility and relieve manufacturers in the area of quality control and release of active ingredients & excipients. The analysis of patient samples in clinical studies is also one of our core competencies. We also have the necessary capacities at short notice to support the pharmaceutical industry in the fight against the coronavirus.
Contact our experts – we will find quick solutions!
Tentamus Group GmbH was founded in 2011. Tentamus is a global product and safety group with a core presence in Europe, UK, Israel, China, Japan, India and the USA. Accredited and licensed Tentamus Group tests, audits and consults on all products involving the human body (food & feed, pharmaceuticals & medical, agrosciences, cosmetics, agriculture & environment and nutraceutical & supplements). Tentamus Group is represented in over 65 locations worldwide. More than 2,500 highly-trained staff members work in over 2.5 million square feet of laboratory and office spaces. For further information please visit www.tentamus.com.
Tentamus Group GmbH
An der Industriebahn 26
13088 Berlin
Telefon: +49 (30) 206038-230
Telefax: +49 (30) 206038-190
http://www.tentamus.com
General Manager Pharma; DSI-pharm
Telefon: +49 441 3613265 449
E-Mail: serap.acikgoez@tentamus.com
Managing Director TentaMedix GmbH
Telefon: +49 174 159 13 40
E-Mail: dominik.herzog@tentamedix.com
Managing Director BLS Analytik
Telefon: +49 971 785 58 0
E-Mail: jochen.kolb@bls-analytik.de
Chief Business Development Officer & Marketing VelaLabs GmbH
Telefon: +43 (1) 890597911
E-Mail: m.roucka@vela-labs.at